Triple-negative breast carcinoma

This phase II trial tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer (stages IB-III). The vaccine is designed to train the immune system to recognize and attack cancer cells that express certain proteins. Participants also recei…

This study tests a cancer vaccine (PVX-410) alone or with an immunotherapy drug (durvalumab) in 22 women with stage II or III triple negative breast cancer who have completed standard treatment. The goal is to see if the vaccine is safe and can boost the immune system to help pre…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This early-phase trial is testing whether giving two drugs—lenvatinib and pembrolizumab—before surgery can boost the immune response in people with early-stage triple-negative breast cancer. Only 12 participants will receive the short treatment before their planned surgery. The m…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This phase II trial is testing a combination of four drugs—trilaciclib, pembrolizumab, gemcitabine, and carboplatin—in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The study aims to see how well the treatment works and how sa…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study …

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This study tests a combination of two drugs, eribulin and copanlisib, in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combo can slow tumor growth better than eribulin alone. About 24 …

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin and paclitaxel) before surgery helps shrink tumors in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or…

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This phase I trial is testing a new drug called ASTX727 (a combination of decitabine and cedazuridine) alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The st…

This phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This phase 3 study compares a new drug, BL-B01D1, to standard chemotherapy in 418 people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth and extend survival. Participants must be…

This phase 2 trial is testing whether combining immunotherapy drugs (pembrolizumab, ipilimumab, nivolumab) with a freezing technique called cryoablation before standard surgery can improve outcomes for women with triple-negative breast cancer. The study enrolls 51 women who have …

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This study tests the drug niraparib in 20 people whose cancer has spread to the brain or spinal cord. The goal is to see if the drug can shrink or control these tumors. Participants must have mild or no symptoms from their brain metastases and not need increasing steroids or seiz…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study tests the safety of specially prepared T cells that target a protein called mesothelin, found on some breast cancer cells. The cells are collected from the patient's blood, modified in a lab, and then given back along with chemotherapy and another drug. The trial enrol…

This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This study tested the drug pembrolizumab in 71 people with advanced inflammatory or triple-negative breast cancer that had spread or returned. Participants had already responded to chemotherapy. The goal was to see if pembrolizumab could keep the cancer from growing for at least …

This study tests a combination of two drugs—sacituzumab govitecan and talazoparib—in people with metastatic triple-negative breast cancer that has spread. The goal is to see if the combo can shrink tumors or slow the disease. About 75 adults with advanced cancer are taking part. …

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …

This large Phase 3 trial tests whether a new combination of drugs (datopotamab deruxtecan plus durvalumab) given before and after surgery works better than the current standard treatment for people with untreated triple-negative or hormone receptor-low/HER2-negative breast cancer…

This study is for people with a certain type of breast cancer (HER2-negative) that has spread to lymph nodes. It tests giving a mix of chemotherapy, an immunotherapy drug (pembrolizumab), and different doses of radiation before surgery. The goal is to see if this approach helps t…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This phase 2 study tested a drug called eribulin followed by standard chemotherapy (doxorubicin and cyclophosphamide) as a preoperative treatment for HER2-negative inflammatory breast cancer, a rare and aggressive form of the disease. The goal was to see if this combination could…

This Phase 2 study tests whether adding another drug (ceralasertib or adavosertib) to the standard drug olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. The trial includes 273 adults whose cancer has specific genetic changes. One…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, and the study is currently active but not …

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adult…

This early-phase study tests a cancer vaccine (PVX-410) alone or with the immunotherapy drug pembrolizumab in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2). The goal is to see if the vaccine safely boosts the immune system to f…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This Phase 3 trial tests whether a new drug, datopotamab deruxtecan (Dato-DXd), given alone or with another drug (durvalumab), can help prevent breast cancer from returning in people with triple-negative breast cancer who still have cancer cells after initial treatment and surger…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests an experimental drug called enfortumab vedotin in 329 adults with advanced solid tumors that have spread. The main goal is to see if the drug shrinks tumors. Researchers also check how long the effect lasts and monitor side effects. Some participants also receive…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this ag…

This study tests two drugs, olaparib and pembrolizumab, given before standard surgery for people with triple-negative or hormone receptor-positive HER2-negative breast cancer who have specific gene mutations. The goal is to see if the combination can shrink tumors enough to impro…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This early-phase trial tests a combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the best dose and see if the combo is safe. Veliparib may help carboplatin work better by stopping cancer cells from r…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This phase 2 trial tests whether giving sacituzumab govitecan and pembrolizumab before surgery can help control early-stage triple-negative breast cancer that didn't respond to initial chemotherapy and immunotherapy. The study enrolls 27 adults with specific tumor types. The main…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA- or PALB2-mutated breast cancer. The goal is to see if this combination boosts the immune system's attack on the tumor and leads to a complete response (no cancer left at surgery). Abo…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This phase 3 trial tests a new drug called Dato-DXd against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to receive either Dato-DXd or one of several chemotherapy dr…

This phase II trial at Mayo Clinic tests whether estradiol, a form of estrogen, can help patients with a specific subtype of triple negative breast cancer that has a receptor called ER beta. The study enrolls 8 women with advanced or metastatic disease. Researchers will measure h…

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This Phase 3 trial tests a new chemotherapy drug called SKB264 against standard chemotherapies in 254 people with advanced triple-negative breast cancer that has worsened after at least two prior treatments. The main goal is to see if SKB264 can delay cancer growth longer than th…

This phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how…

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plu…

This phase 2 trial tests whether adding an immunotherapy drug called IRX 2 to standard pembrolizumab (Keytruda) and chemotherapy can improve outcomes for people with triple-negative breast cancer. The study involves 12 participants who receive the combination before surgery. The …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took …

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants…

This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard…

This study tests whether giving the immunotherapy drug pembrolizumab (Keytruda) along with a small dose of radiation to the tumor before standard treatment (surgery, chemotherapy, or radiation) is safe and helps the immune system fight breast cancer. About 66 people with operable…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This early-phase trial tests a new treatment for metastatic triple-negative breast cancer, a type that has spread and is hard to treat. The treatment uses a specially designed virus that is injected directly into tumors to infect and destroy cancer cells. The main goal is to find…

This study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before …

This Phase 2 study tests a drug called zelenectide pevedotin in 66 people with advanced breast cancer that has a specific gene change (NECTIN4 amplification). The study includes two groups: one with hormone receptor-positive/HER2-negative cancer and one with triple-negative breas…

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…

This phase 3 study compares a targeted drug called sacituzumab govitecan against standard chemotherapy in about 623 people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). Participants either have not received prio…

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…

This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer retu…

This phase II trial is testing whether a pre-treatment biopsy can predict how well patients with locally recurrent or metastatic triple negative breast cancer respond to cisplatin chemotherapy combined with radiation therapy. About 49 participants will receive the treatment, and …

This study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated yet. About 120 participants will receive the combination. The main goals are to see h…

This early-phase study planned to test whether injecting the seasonal flu vaccine directly into breast tumors could help the immune system attack the cancer. It was designed for women with triple-negative or HER2+ breast cancer who were already scheduled for chemotherapy before s…

This phase 2 study tests a combination of camrelizumab (an immunotherapy), risedronate (a bone drug), and chemotherapy in 30 women with triple-negative breast cancer. The goal is to see if adding risedronate can help overcome resistance to standard treatment and improve tumor shr…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This phase 2 trial is testing whether combining an experimental pill (CFI-400945) with an immunotherapy drug (durvalumab) can shrink tumors in 15 women with advanced triple negative breast cancer that has spread or cannot be removed. The study measures how many participants see t…

This study was designed to test whether adding the experimental drug boserolimab to standard chemotherapy and immunotherapy before surgery could help people with high-risk, early-stage triple-negative breast cancer. The goal was to see if the combination was safe and could elimin…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…

This study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in 81 women with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced (metastatic) cancer. The goal is to see if the …

This study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors or slow the disease. Participants receive the drug intr…

This study tests whether giving stereotactic body radiotherapy (SBRT) to growing metastatic tumors can delay overall cancer progression. About 107 adults with triple-negative breast cancer or non-small cell lung cancer that has started to grow in a few spots will receive SBRT or …

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This study tests a new drug called HB0025 combined with chemotherapy (nab-paclitaxel) as a first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal is to see if the combination is safe and works better than chemotherapy al…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This phase 3 trial tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that has worsened after taxane treatment. The study compares how long the cancer stays under control and overall survival. Participants ar…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This study tests a combination of two drugs, sacituzumab govitecan and bevacizumab, in people with metastatic triple-negative breast cancer that has progressed after at least one prior treatment. The trial will enroll 60 participants across several centers in China. Researchers w…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This study tests a combination of two drugs, ribociclib and bicalutamide, in people with advanced triple-negative breast cancer that has a specific marker (androgen receptor). The goal is to see if the combo can shrink tumors or stop them from growing. 37 participants are enrolle…

This phase 3 trial tests whether adding capivasertib (a targeted drug) to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants receive either the combination or a placebo plus chemotherapy. The study is no…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-n…

This early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This Phase 2 trial is testing a combination of two chemotherapy drugs, liposomal doxorubicin and carboplatin, given after surgery to people with early-stage triple negative breast cancer. The goal is to see if this treatment can reduce the risk of the cancer coming back. The stud…

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This study tests a combination of three drugs—cisplatin, romidepsin, and nivolumab—in people with advanced triple-negative breast cancer or BRCA-related breast cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. About 51 partic…

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…

This early-phase study tests a new drug called BL-M02D1 in people with advanced triple negative breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors.…

This phase 3 trial tests whether combining sacituzumab govitecan (Trodelvy) with pembrolizumab (Keytruda) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a protein called PD-L1. About 443 participants who …

This phase 3 trial tests whether adding the drug capecitabine to standard chemotherapy improves outcomes for people with early triple-negative breast cancer. The study involves 325 participants and aims to see if the combination leads to a higher rate of complete tumor disappeara…

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-stage trial is testing whether a new radioactive imaging agent, called [99mTc]Tc-DARPinEc1-G3C, can safely and effectively visualize breast cancer tumors using SPECT/CT imaging. The study involves about 10 people with primary triple-negative or luminal breast cancer. P…

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple…

This pilot study aimed to see if contrast-enhanced ultrasound (CEUS) could predict how well triple-negative breast cancer patients respond to chemotherapy and immunotherapy. Researchers planned to measure tumor volume and blood flow changes with CEUS before and during treatment. …

This study looks at whether a breast MRI-guided biopsy can accurately tell if a woman's breast cancer has completely disappeared after chemotherapy. Researchers will enroll 31 women whose tumors are no longer visible on MRI after treatment. If the biopsy correctly identifies a co…

Researchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…

This study tests whether a less invasive ultrasound-guided biopsy can accurately tell if breast cancer has been completely wiped out by chemotherapy, compared to the standard method of checking during surgery. About 43 women with aggressive breast cancer types (triple negative or…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…

This study explores whether a special MRI scan can serve as a non-invasive biomarker to predict how early breast cancer responds to immunotherapy. Researchers will compare MRI features with tissue and blood samples from about 10 patients with hormone receptor-negative, HER2-negat…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study was designed to see if a blood test that looks for tiny pieces of tumor DNA (called ctDNA) could find leftover cancer cells in people with early-stage breast cancer after standard treatment. The goal was to help doctors decide who might need more therapy. However, the …

This observational study tracks how doctors treat advanced triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will look at real-world data from 760 patients to understand treatment patterns and outcomes. No new drugs are being tested—the goal is to ga…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatm…

This study looks at how well the body of women with early triple-negative breast cancer can switch between burning fat and sugar for energy—a trait called metabolic flexibility. Researchers will test if different types of exercise (moderate cardio, high-intensity cardio, or stren…

This study looks at whether certain blood cell counts and tumor-infiltrating lymphocytes can help predict if triple negative breast cancer will come back. Researchers will collect blood samples from 90 women after radiation and at the time of any first recurrence. The goal is to …

This study was designed to see if a 14-day course of the drug Anakinra could change the immune environment around early-stage triple-negative or ER-low breast tumors. It was planned for people with small, early-stage tumors who were not scheduled for chemotherapy before surgery. …

This study takes tumor tissue from 50 women with invasive breast cancer and grows mini 3D versions called organoids in the lab. These organoids are used to collect tiny particles called extracellular vesicles, which naturally seek out tumor cells. The goal is to use these particl…

This pilot study is testing whether a personalized blood test that looks for leftover tumor DNA can help doctors make better treatment decisions for people with early-stage breast cancer. About 34 participants with triple-negative or HER2-positive breast cancer will receive chemo…

This trial was designed to test whether an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The study planned to compare the online program to standard educational materials. Howev…

This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and d…

This study looks at 197 women with advanced breast cancer to compare survival between those whose tumors lost estrogen receptors (ER) and those with triple-negative disease. Researchers used a special PET scan to track receptor changes. The goal is to understand how these changes…

This trial was designed to test whether adding aspirin to the immunotherapy drug avelumab could help the immune system fight triple-negative breast cancer. Participants would have received either avelumab alone or with aspirin for about 18 days, with biopsies and blood tests to m…

This study looks at whether a set of proteins in the blood can predict if triple-negative breast cancer will come back after treatment. Researchers will follow 90 women and test their blood at several time points. The goal is to find a simple way to identify patients who need clo…

This study looks at whether a genetic test (BRCA1-like) can help doctors choose the best first chemotherapy for people with advanced triple-negative breast cancer. About 304 participants will receive either carboplatin-cyclophosphamide or paclitaxel, with or without the immunothe…

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…